Pharma tactics 'unfair,' say advocates

Share this article:
Pharma advertisers use an array of tactics to gather information about online health seekers in a way that is unfair and deceptive, consumer advocates have charged in a complaint filed with the FTC. Moreover, the advocates say, the agency should be allowed time to investigate these stealth practices and issue safeguards before the FDA issues rules for social media advertising.
Nearly $1 billion dollars will be spent this year by online health and medical marketers targeting US consumers, according to the complaint.
The groups issuing the complaint are the Center for Digital Democracy (CDD), US PIRG, Consumer Watchdog and the World Privacy Forum. Several tactics, they argue, pose a threat:
  • Condition targeting based on a person's use of online health information services and digital behaviors;
  • Eavesdropping on online discussions via social media data mining, enabling pharmas to hone marketing campaigns; and
  • Contextually relevant advertising via online profiling and behavioral tracking.
These digital marketing tools give pharmaceutical and online health information companies “unprecedented abilities to take advantage of consumers,” said Jeff Chester, CDD executive director, in a statement.
Companies named in the filing include Google, Yahoo, Microsoft, AOL, WebMD, QualityHealth, Everyday Health and Health Central.
Rob Rebak, CEO of QualityHealth said sites that collect information don't necessarily run afoul of user privacy. It depends on where their ability to target consumers comes from.
“If that ability is coming explicitly from information that health consumers are directly volunteering to a company like QualityHealth, which utilizes a fully transparent permission-based model, then this is not at odds,” he told MM&M in an email. “For other sites that may be using implicit information-gathering and -guessing techniques, often generally referred to under the umbrella of ‘behavioral targeting,' user privacy may be more of an issue.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?